Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 17, 2017

Primary Completion Date

March 31, 2024

Study Completion Date

December 31, 2024

Conditions

Metastatic Prostate CarcinomaRecurrent Prostate CarcinomaStage IV Prostate Cancer

Interventions

DRUG

Enzalutamide

Given PO

DRUG

Indomethacin

Given PO

Trial Locations (1)

RECRUITING

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Mamta Parikh

OTHER